Clinical Trial Search

Primary: Number of Participants by Buttock at Each Level of Bruising on the Investigator Assessment of Bruising Severity Scale at Day 4 — 0; 0; 0; 0 Participants

Primary: Cohort 1: Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval at Steady State (AUC[0-tau]) of GSK3640254 — 27.03; 30.70…

Primary: Change in % Blood Oxygenation Level Dependent Change (%BOLD) in the Nucleus Accumbens — -0.08 %BOLD signal change

Primary: Muscle Thickness Change of Transverse Abdominis — 0.93; 0.77; 1.98; 0.99 mm

Primary: Part A: PF-06882961 Maximum Observed Concentration (Cmax) — 15.69; 17.09 nanogram per milliliter (ng/mL)

Primary: Change From Baseline to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score — -0.784; -3.370; -3.403 units on a scale — p=<0.001

Primary: Percentage of Patients With Treatment-emergent Adverse Events Related to BI 894416 — 0; 28.6; 37.5; 62.5 Percentage of participants

Primary: Cognitive Assessment Using MoCA Version 7.1 Scores — 25.45; 27 units on a scale

Primary: Change From Baseline in Objective Physical Activity at 4 Months — 3155; 1581 steps/week

Primary: Acceptability of Intervention: "Satisfaction Questionnaire" — 9.83; 9.33; 9.33; 9.82 score on a scale

Primary: Changes in the Mean Daily Numerical Rating Scale (NRS) Scores for the Worst Endometriosis-related Pain. — -0.66; -2.04; -2.14; -3.68 score on a scale

Primary: Biphasic Alcohol Effects Scale (BAES): Stimulant Subscale — 13.756; 14.053; 13.026 score on a scale — p=0.867

Primary: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 41.6; 1.1 Percentage of participants

Primary: Response to Treatment by RECIST Criteria — 3; 3; 48; 47 Participants

Primary: Number of Participants Categorized According to Type of Index Combination Treatment Regimen — 293; 266 Participants